[go: up one dir, main page]

MX2020006014A - Compuestos de diazaindol. - Google Patents

Compuestos de diazaindol.

Info

Publication number
MX2020006014A
MX2020006014A MX2020006014A MX2020006014A MX2020006014A MX 2020006014 A MX2020006014 A MX 2020006014A MX 2020006014 A MX2020006014 A MX 2020006014A MX 2020006014 A MX2020006014 A MX 2020006014A MX 2020006014 A MX2020006014 A MX 2020006014A
Authority
MX
Mexico
Prior art keywords
compounds
diazaindole
disclosed
toll
inhibitors
Prior art date
Application number
MX2020006014A
Other languages
English (en)
Inventor
Alaric J Dyckman
Dharmpal S Dodd
Christopher P Mussari
Sreekantha Ratna Kumar
Brian K Whiteley
Reddy Anupama Kandhi Ramachandra
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2020006014A publication Critical patent/MX2020006014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de Fórmula (I) (ver formula I) N-óxidos, o sales de los mismos, en donde G, A, X, Y, Z, R1, y n se definen en la presente. También se describen métodos para usar tales compuestos como inhibidores de la señalización a través del receptor similar a Toll 7, o 8, o 9, y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son útiles en el tratamiento de enfermedades inflamatorias y autoinmunes.
MX2020006014A 2017-12-20 2018-12-18 Compuestos de diazaindol. MX2020006014A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607941P 2017-12-20 2017-12-20
PCT/US2018/066108 WO2019126083A1 (en) 2017-12-20 2018-12-18 Diazaindole compounds

Publications (1)

Publication Number Publication Date
MX2020006014A true MX2020006014A (es) 2020-08-17

Family

ID=65003573

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006014A MX2020006014A (es) 2017-12-20 2018-12-18 Compuestos de diazaindol.

Country Status (14)

Country Link
US (1) US11299501B2 (es)
EP (1) EP3728264B1 (es)
JP (1) JP7382938B2 (es)
KR (1) KR102722182B1 (es)
CN (1) CN111511744B (es)
AU (1) AU2018390544A1 (es)
BR (1) BR112020012002A2 (es)
CA (1) CA3085937A1 (es)
EA (1) EA202091530A1 (es)
ES (1) ES2904773T3 (es)
IL (1) IL275505A (es)
MX (1) MX2020006014A (es)
SG (1) SG11202005733QA (es)
WO (1) WO2019126083A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
ES2965182T3 (es) * 2017-12-20 2024-04-11 Bristol Myers Squibb Co Compuestos de indol sustituidos con arilo y heteroarilo
SG11202005694RA (en) * 2017-12-20 2020-07-29 Bristol Myers Squibb Co Amino indole compounds useful as tlr inhibitors
WO2019155042A1 (en) 2018-02-12 2019-08-15 F. Hoffmann-La Roche Ag Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2020012827A (es) 2018-06-05 2021-02-15 Hoffmann La Roche Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes.
WO2019238616A1 (en) 2018-06-12 2019-12-19 F. Hoffmann-La Roche Ag Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
US11952363B2 (en) 2018-07-23 2024-04-09 Hoffmann-La Roche Inc. Piperazine compounds for the treatment of autoimmune disease
EP3847169A1 (en) 2018-09-04 2021-07-14 F. Hoffmann-La Roche AG Benzothiazole compounds for the treatment of autoimmune diseases
WO2020048595A1 (en) 2018-09-06 2020-03-12 F. Hoffmann-La Roche Ag Novel cyclic amidine compounds for the treatment of autoimmune disease
US12252484B2 (en) 2018-09-06 2025-03-18 Hoffmann-La Roche Inc. Pyrazolopyridine compounds for the treatment of autoimmune disease
CN114599652B (zh) 2019-10-31 2024-07-12 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物
EP4061816A1 (en) 2019-11-19 2022-09-28 F. Hoffmann-La Roche AG Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
WO2021099406A1 (en) 2019-11-20 2021-05-27 F. Hoffmann-La Roche Ag Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease
TW202227432A (zh) 2020-08-19 2022-07-16 美商必治妥美雅史谷比公司 可做為tlr9抑制劑之經取代雙環化合物
AU2021329323A1 (en) 2020-08-19 2023-03-16 Bristol-Myers Squibb Company 1H-benzo(d)imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis
CN116848119A (zh) * 2021-02-08 2023-10-03 杭州中美华东制药有限公司 一种吡咯并哒嗪类化合物及其制备方法和用途
CN116783202A (zh) * 2021-02-09 2023-09-19 吉利德科学公司 噻吩并吡咯化合物
PE20240919A1 (es) 2021-04-16 2024-04-30 Gilead Sciences Inc Compuestos de tienopirrol
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
WO2023159154A1 (en) * 2022-02-18 2023-08-24 Bristol-Myers Squibb Company Substituted imidazopyridinyl compounds useful as inhibitors of tlr9
CN114591339B (zh) * 2022-05-10 2022-08-02 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
EA200100675A1 (ru) 1998-12-18 2001-12-24 Аксис Фармасьютикалз, Инк. Ингибиторы протеазы
SK286628B6 (sk) 1999-10-19 2009-02-05 Merck & Co., Inc. Inhibítory tyrozín-kinázy, farmaceutický prostriedok s ich obsahom a ich použitie
ES2262996T3 (es) 2002-01-07 2006-12-01 Eisai Co., Ltd. Deazapurinas y sus usos.
US7410975B2 (en) 2003-06-20 2008-08-12 Coley Pharmaceutical Group, Inc. Small molecule toll-like receptor (TLR) antagonists
WO2007115306A2 (en) 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
US20060235037A1 (en) * 2005-04-15 2006-10-19 Purandare Ashok V Heterocyclic inhibitors of protein arginine methyl transferases
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
JP2010511018A (ja) 2006-12-01 2010-04-08 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なトリアゾロピリジン化合物
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
EP2205085A1 (en) 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
WO2010036905A1 (en) 2008-09-26 2010-04-01 Eisai R & D Management Co., Ltd. Benzoxazole compounds and methods of use
WO2010045188A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
WO2011009015A1 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
CA2771026A1 (en) 2009-09-24 2011-03-31 F. Hoffmann-La Roche Ag Indole derivatives as crac modulators
MX2012004792A (es) 2009-10-22 2013-02-01 Vertex Pharma Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
JP2013166700A (ja) * 2010-06-02 2013-08-29 Dainippon Sumitomo Pharma Co Ltd 新規４，５−縮環ピリミジン誘導体
WO2012054862A2 (en) 2010-10-21 2012-04-26 The Brigham And Women's Hospital, Inc. Agents, compositions, and methods for treating pruritis and related skin conditions
CA2824786A1 (en) 2011-01-12 2012-07-19 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
HRP20170401T1 (hr) 2011-01-12 2017-05-19 Ventirx Pharmaceuticals, Inc. SUPSTITUIRANI BENZOAZEPINI KAO MODULATORI TOLL-u SLIČNIH RECEPTORA
AU2012262021B2 (en) 2011-06-01 2016-07-28 Janus Biotherapeutics, Inc. Novel immune system modulators
KR102052215B1 (ko) 2011-06-01 2019-12-04 야누스 바이오테라퓨틱스, 인크. 신규한 면역 시스템 조절제
ES2602813T3 (es) 2011-06-09 2017-02-22 Rhizen Pharmaceuticals S.A. Nuevos compuestos como moduladores de GPR-119
AU2012285931B2 (en) 2011-07-15 2017-01-12 Cellzome Limited Novel substituted indole derivatives as gamma secretase modulators
JP2013075834A (ja) * 2011-09-29 2013-04-25 Kowa Co Ｔｌｒ９阻害活性を有するピラゾロピリミジン−７−アミン誘導体
AU2012318694B2 (en) 2011-10-04 2016-12-22 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
WO2013092444A1 (en) 2011-12-20 2013-06-27 F. Hoffmann-La Roche Ag Diazaindole inhibitors of crac
JP6184423B2 (ja) 2012-05-18 2017-08-23 大日本住友製薬株式会社 カルボン酸化合物
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
JP6223563B2 (ja) 2013-10-14 2017-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物
JP2016540013A (ja) 2013-12-13 2016-12-22 武田薬品工業株式会社 Ｔｌｒ阻害剤としてのピロロ［３，２−ｃ］ピリジン誘導体
CN106661034B (zh) 2014-08-15 2019-11-29 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
EP3183251A4 (en) 2014-08-22 2017-12-27 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
ES2863474T3 (es) 2016-07-30 2021-10-11 Bristol Myers Squibb Co Compuestos de indol sustituidos con dimetoxifenilo como inhibidores de TLR7, TLR8 o TLR9
EP3510024B1 (en) 2016-09-09 2021-11-17 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
WO2019099336A1 (en) 2017-11-14 2019-05-23 Bristol-Myers Squibb Company Substituted indole compounds
MX2020006168A (es) 2017-12-18 2020-08-13 Bristol Myers Squibb Co Compuestos de 4-azaindol.
EP3728253B1 (en) 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds

Also Published As

Publication number Publication date
WO2019126083A1 (en) 2019-06-27
JP7382938B2 (ja) 2023-11-17
CN111511744A (zh) 2020-08-07
KR102722182B1 (ko) 2024-10-24
ES2904773T3 (es) 2022-04-06
EA202091530A1 (ru) 2020-09-14
EP3728264B1 (en) 2021-12-01
EP3728264A1 (en) 2020-10-28
JP2021506941A (ja) 2021-02-22
IL275505A (en) 2020-08-31
KR20200100760A (ko) 2020-08-26
US20200308195A1 (en) 2020-10-01
SG11202005733QA (en) 2020-07-29
AU2018390544A1 (en) 2020-08-06
BR112020012002A2 (pt) 2020-11-17
CN111511744B (zh) 2023-09-22
US11299501B2 (en) 2022-04-12
CA3085937A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
MX2020006014A (es) Compuestos de diazaindol.
MX2020005873A (es) Compuestos de 6-azaindol.
MX2020006168A (es) Compuestos de 4-azaindol.
MX2020005462A (es) Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr).
MX2020005622A (es) Compuestos de indol sustituidos con arilo y heteroarilo.
MX2020006093A (es) Compuestos de indol eter sustituidos.
MX2020005515A (es) Compuestos de indol sustituidos con amida, utiles como inhibidores de receptores de tipo toll (tlr).
MX2020005513A (es) Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr).
EA201990169A1 (ru) Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9
MY196474A (en) [1,2,4]Triazolo[1,5-A]Pyridinyl Substituted Indole Compounds
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
PH12018501920A1 (en) Bromodomain inhibitors
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
MY210123A (en) Tlr7/8 antagonists and uses thereof
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
MX2021003792A (es) Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
PH12019500196A1 (en) Compounds and compositions and uses thereof
JOP20190174B1 (ar) مثبطات jak1 انتقائية
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
PH12018500406A1 (en) Bicyclic compounds as atx inhibitors